In a first cohort, approximately half of patients with metastatic melanoma or synovial cell sarcoma who received NY-ESO-1 transduced CD8+ T cells and IL-2 showed a clinical response (106). The gene discussed is CTAG1B; the disease is metastatic melanoma.